VNDA

Business Context and Reporting Period

Company: Vanda Pharmaceuticals Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Stage: Development Stage Enterprise
Overview: Vanda is a biopharmaceutical company focused on central nervous system disorders. Its lead product, Fanapt (iloperidone) for schizophrenia, received FDA approval in May 2009. On October 12, 2009, Vanda entered into an amended and restated sublicense agreement with Novartis, granting Novartis exclusive commercialization rights in the U.S. and Canada. Vanda retains rights outside these regions. The company has no product revenues to date and relies on external financing and milestone payments.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by approximately $3.5 million (31%) for the three months ended September 30, 2009, compared to the same period in 2008. This was driven by a 44.8% decrease in R&D expenses and a 28.8% decrease in G&A expenses, largely due to a workforce reduction in late 2008 and the completion of Phase III trials for tasimelteon.
• Intangible Assets: A new intangible asset of $12.0 million was capitalized in May 2009 following FDA approval of Fanapt, representing a milestone payment to Novartis. This asset is being amortized over the patent life (estimated through 2017).
• Inventory: Inventory increased to $1.76 million as of September 30, 2009, from zero in the prior year, as manufacturing costs for Fanapt were capitalized post-FDA approval.
• Liquidity: Cash and cash equivalents decreased from $39.1 million at December 31, 2008, to $17.4 million at September 30, 2009, primarily due to operating cash outflows and a $7.0 million milestone payment to Novartis.

Guidance, Outlook, and Risks

• Novartis Agreement: Vanda expects to receive an upfront payment of $200.0 million from Novartis within 30 days of the agreement's effective date (expected by end of 2009). Additional milestone payments up to $265.0 million and low double-digit royalties on net sales in the U.S. and Canada are contingent on future commercial success.
• Commercial Launch: Novartis is expected to launch Fanapt in the U.S. in the first quarter of 2010. Vanda will not be involved in U.S./Canada marketing but retains rights outside these regions.
• Spending Plan: Management expects to operate on a reduced spending plan with fixed overhead costs of approximately $2.5 million to $3.0 million per quarter.
• Risks:
  • Dependence on Novartis for U.S./Canada commercialization success.
  • Need for additional capital if the Novartis upfront payment is delayed or if development costs for other products (e.g., tasimelteon) exceed expectations.
  • Regulatory risks regarding the Hatch-Waxman patent extension for Fanapt.
  • Market acceptance and competition for Fanapt and tasimelteon.

Investor Verification Checklist

• Novartis Deal Closing: Verify the effective date of the amended and restated sublicense agreement and the receipt of the $200 million upfront payment.
• Cash Runway: Assess whether the $20.7 million in current liquid assets is sufficient to fund operations until the Novartis payment is received and for the development of tasimelteon.
• Patent Extension: Confirm the status of the Hatch-Waxman patent extension application for Fanapt, which impacts the amortization period of the $12 million intangible asset.
• Inventory Obligation: Verify that Novartis has committed to purchasing the $1.76 million of Fanapt inventory upon the agreement's effective date.
• Success Fees: Monitor the payment of the $3.5 million success fee to strategic advisors contingent on the Novartis deal closing.